- Home
- GROW vs ACRV Comparison
GROW vs ACRV Comparison
Compare GROW & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROW
- ACRV
- Stock Information
- Founded
- GROW 1968
- ACRV 2018
- Country
- GROW United States
- ACRV United States
- Employees
- GROW N/A
- ACRV N/A
- Industry
- GROW Investment Managers
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- GROW Finance
- ACRV Health Care
- Exchange
- GROW Nasdaq
- ACRV Nasdaq
- Market Cap
- GROW 31.8M
- ACRV 34.5M
- IPO Year
- GROW N/A
- ACRV 2022
- Fundamental
- Price
- GROW $2.48
- ACRV $1.31
- Analyst Decision
- GROW
- ACRV Buy
- Analyst Count
- GROW 0
- ACRV 7
- Target Price
- GROW N/A
- ACRV $17.60
- AVG Volume (30 Days)
- GROW 28.3K
- ACRV 466.7K
- Earning Date
- GROW 05-08-2025
- ACRV 08-12-2025
- Dividend Yield
- GROW 3.63%
- ACRV N/A
- EPS Growth
- GROW N/A
- ACRV N/A
- EPS
- GROW 0.01
- ACRV N/A
- Revenue
- GROW $8,932,000.00
- ACRV N/A
- Revenue This Year
- GROW N/A
- ACRV N/A
- Revenue Next Year
- GROW N/A
- ACRV N/A
- P/E Ratio
- GROW $232.40
- ACRV N/A
- Revenue Growth
- GROW N/A
- ACRV N/A
- 52 Week Low
- GROW $2.02
- ACRV $1.05
- 52 Week High
- GROW $2.73
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- GROW 70.53
- ACRV 51.85
- Support Level
- GROW $2.30
- ACRV $1.15
- Resistance Level
- GROW $2.45
- ACRV $1.30
- Average True Range (ATR)
- GROW 0.07
- ACRV 0.09
- MACD
- GROW 0.00
- ACRV 0.03
- Stochastic Oscillator
- GROW 100.00
- ACRV 61.54
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.